Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nutriband Inc. (NTRB : NSDQ)

• Company Description    Nutriband Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company is engaged in developing to provide clinicians and patients with an abuse deterrent transdermal fentanyl product for use in managing chronic pain requiring opioid therapy. Nutriband Inc. is based in Orlando, United States. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $6.03 Daily Weekly Monthly 20 Day Moving Average: 42,481 shares Shares Outstanding: 12.03 (millions) Market Capitalization: $72.57 (millions) Beta: 1.54 52 Week High: $9.42 52 Week Low: $2.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.71% -21.81% 12 Week -8.22% -12.02% Year To Date 28.02% 11.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 121 South Orange Ave. Suite 1500 - Orlando,FL 32801 USA ph: 407-377-6695 fax: - investor.relations@nutriband.com http://www.nutriband.com

• General Corporate Information    Officers Gareth Sheridan - Chief Executive Officer Serguei Melnik - Chairman of the Board; President and Secretary Alan Smith - Chief Operating Officer and President Gerald Goodman - Chief Financial Officer Serguei Melnik - Director Peer Information Nutriband Inc. (GSAC) Nutriband Inc. (CASI) Nutriband Inc. (ALCD.) Nutriband Inc. (OMNN) Nutriband Inc. (CGPI.) Nutriband Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 67092M208 SIC: 3842 Fiscal Year Fiscal Year End: January Last Reported Quarter: 07/01/25 Next Expected EPS Date: 12/02/25 Share - Related Items Shares Outstanding: 12.03 Most Recent Split Date: 8.00 (1.17:1) Beta: 1.54 Market Capitalization: $72.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.89 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 12/02/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.92 Price/Cash Flow: - Price / Sales: 28.15 EPS Growth vs. Year Ago Period: -1,666.67% vs. Previous Quarter: -1,666.67% Sales Growth vs. Year Ago Period: 40.63% vs. Previous Quarter: -6.60% ROE 10/31/25 - - 07/31/25 - -85.40 04/30/25 - -68.25 ROA 10/31/25 - - 07/31/25 - -73.45 04/30/25 - -60.40 Current Ratio 10/31/25 - - 07/31/25 - 4.78 04/30/25 - 3.71 Quick Ratio 10/31/25 - - 07/31/25 - 4.70 04/30/25 - 3.48 Operating Margin 10/31/25 - - 07/31/25 - -258.84 04/30/25 - -250.63 Net Margin 10/31/25 - - 07/31/25 - -398.29 04/30/25 - -415.93 Pre-Tax Margin 10/31/25 - - 07/31/25 - -398.33 04/30/25 - -415.93 Book Value 10/31/25 - - 07/31/25 - 0.76 04/30/25 - 0.46 Inventory Turnover 10/31/25 - - 07/31/25 - 9.23 04/30/25 - 7.65 Debt-to-Equity 10/31/25 - - 07/31/25 - 0.01 04/30/25 - 0.01 Debt-to-Capital 10/31/25 - - 07/31/25 - 0.55 04/30/25 - 1.02

Powered by Zacks Investment Research ©